Sunday, May 27, 2007

Vioxx, Avandia, what next?

From the Associated Press:
How does a drug go from blockbuster to bust?

How can big safety issues go undetected in medicines taken by millions of people for many years, as happened this week with the diabetes pill Avandia and a few years ago with the painkiller Vioxx?

Or with devices like drug-coated stents, which came under a cloud last year after six million heart patients had already received them?

All roads - and fingers this week - point to the U.S. Food and Drug Administration. From a company's labs to a consumer's lips, the chronically understaffed federal agency has the power and duty to keep dangerous products from harming the public. ...more

No comments: